Multiagent targeting of neuroendocrine neoplasms

Duccio Volterrani, Federica Orsini, Serena Chiacchio, Lisa Bodei

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

In the field of nuclear medicine, multiagent imaging can disclose enhanced expression of specific target molecules of neoplastic cells. This molecular information can be combined with the information provided by anatomical imaging. Over the past 20 years the use of radiolabeled somatostatin analogs as high-affinity tracers binding specifically to somatostatin receptors has allowed successful molecular imaging of neuroendocrine neoplasms (NENs), initially with single-photon-emitting radiopharmaceuticals, and subsequently also with positron-emitting radiopharmaceuticals. In this context, whole-body somatostatin receptor scintigraphy has changed the diagnostic and therapeutic approach to patients with NENs; moreover, somatostatin analog positron emission tomography (PET) tracers that allow higher spatial resolution imaging have recently been introduced. Nevertheless, several NENs can also be successfully imaged with radioagents that target the catecholamine pathway. Although radioiodinated meta-iodobenzylguanidine (MIBG) is traditionally the first option for radionuclide imaging and treatment of these NENs, the use of PET with 18F-l-dihydroxyphenylalanine is being increasingly reported, this approach showing several advantages over conventional imaging. Moreover, changes in tumor biology can be characterized by modifications in receptor or transporter expression on the cell membrane, and evidence has recently emerged that NENs expressing glucose transporters are more aggressive than tumors with low expression of glucose transporters. Therefore, [18F]FDG PET could provide prognostic information useful for stratifying patients according to their risk and for planning the correct therapy. The identification of new radiopharmaceuticals specific for different targets will constitute the basis not only of new diagnostic imaging approaches, but also of new therapeutic applications in NENs, besides radiolabeled peptide receptor radionuclide and 131I-MIBG therapy.

Original languageEnglish
Pages (from-to)407-421
Number of pages15
JournalClinical and Translational Imaging
Volume1
Issue number6
DOIs
Publication statusPublished - 2013

Fingerprint

Radiopharmaceuticals
Neoplasms
Positron-Emission Tomography
3-Iodobenzylguanidine
Somatostatin Receptors
Facilitative Glucose Transport Proteins
Somatostatin
Radionuclide Imaging
Therapeutics
Dihydroxyphenylalanine
Molecular Imaging
Peptide Receptors
Nuclear Medicine
Fluorodeoxyglucose F18
Diagnostic Imaging
Photons
Radioisotopes
Catecholamines
Cell Membrane
Electrons

Keywords

  • DOTA PET
  • F-DOPA PET
  • MIBG
  • Neuroendocrine neoplasms
  • PRRT
  • Somatostatin receptor scintigraphy

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Volterrani, D., Orsini, F., Chiacchio, S., & Bodei, L. (2013). Multiagent targeting of neuroendocrine neoplasms. Clinical and Translational Imaging, 1(6), 407-421. https://doi.org/10.1007/s40336-013-0043-x

Multiagent targeting of neuroendocrine neoplasms. / Volterrani, Duccio; Orsini, Federica; Chiacchio, Serena; Bodei, Lisa.

In: Clinical and Translational Imaging, Vol. 1, No. 6, 2013, p. 407-421.

Research output: Contribution to journalArticle

Volterrani, D, Orsini, F, Chiacchio, S & Bodei, L 2013, 'Multiagent targeting of neuroendocrine neoplasms', Clinical and Translational Imaging, vol. 1, no. 6, pp. 407-421. https://doi.org/10.1007/s40336-013-0043-x
Volterrani, Duccio ; Orsini, Federica ; Chiacchio, Serena ; Bodei, Lisa. / Multiagent targeting of neuroendocrine neoplasms. In: Clinical and Translational Imaging. 2013 ; Vol. 1, No. 6. pp. 407-421.
@article{513e1a351e1d4e80b696b06d478bfd7d,
title = "Multiagent targeting of neuroendocrine neoplasms",
abstract = "In the field of nuclear medicine, multiagent imaging can disclose enhanced expression of specific target molecules of neoplastic cells. This molecular information can be combined with the information provided by anatomical imaging. Over the past 20 years the use of radiolabeled somatostatin analogs as high-affinity tracers binding specifically to somatostatin receptors has allowed successful molecular imaging of neuroendocrine neoplasms (NENs), initially with single-photon-emitting radiopharmaceuticals, and subsequently also with positron-emitting radiopharmaceuticals. In this context, whole-body somatostatin receptor scintigraphy has changed the diagnostic and therapeutic approach to patients with NENs; moreover, somatostatin analog positron emission tomography (PET) tracers that allow higher spatial resolution imaging have recently been introduced. Nevertheless, several NENs can also be successfully imaged with radioagents that target the catecholamine pathway. Although radioiodinated meta-iodobenzylguanidine (MIBG) is traditionally the first option for radionuclide imaging and treatment of these NENs, the use of PET with 18F-l-dihydroxyphenylalanine is being increasingly reported, this approach showing several advantages over conventional imaging. Moreover, changes in tumor biology can be characterized by modifications in receptor or transporter expression on the cell membrane, and evidence has recently emerged that NENs expressing glucose transporters are more aggressive than tumors with low expression of glucose transporters. Therefore, [18F]FDG PET could provide prognostic information useful for stratifying patients according to their risk and for planning the correct therapy. The identification of new radiopharmaceuticals specific for different targets will constitute the basis not only of new diagnostic imaging approaches, but also of new therapeutic applications in NENs, besides radiolabeled peptide receptor radionuclide and 131I-MIBG therapy.",
keywords = "DOTA PET, F-DOPA PET, MIBG, Neuroendocrine neoplasms, PRRT, Somatostatin receptor scintigraphy",
author = "Duccio Volterrani and Federica Orsini and Serena Chiacchio and Lisa Bodei",
year = "2013",
doi = "10.1007/s40336-013-0043-x",
language = "English",
volume = "1",
pages = "407--421",
journal = "Clinical and Translational Imaging",
issn = "2281-5872",
publisher = "Springer-Verlag Italia s.r.l.",
number = "6",

}

TY - JOUR

T1 - Multiagent targeting of neuroendocrine neoplasms

AU - Volterrani, Duccio

AU - Orsini, Federica

AU - Chiacchio, Serena

AU - Bodei, Lisa

PY - 2013

Y1 - 2013

N2 - In the field of nuclear medicine, multiagent imaging can disclose enhanced expression of specific target molecules of neoplastic cells. This molecular information can be combined with the information provided by anatomical imaging. Over the past 20 years the use of radiolabeled somatostatin analogs as high-affinity tracers binding specifically to somatostatin receptors has allowed successful molecular imaging of neuroendocrine neoplasms (NENs), initially with single-photon-emitting radiopharmaceuticals, and subsequently also with positron-emitting radiopharmaceuticals. In this context, whole-body somatostatin receptor scintigraphy has changed the diagnostic and therapeutic approach to patients with NENs; moreover, somatostatin analog positron emission tomography (PET) tracers that allow higher spatial resolution imaging have recently been introduced. Nevertheless, several NENs can also be successfully imaged with radioagents that target the catecholamine pathway. Although radioiodinated meta-iodobenzylguanidine (MIBG) is traditionally the first option for radionuclide imaging and treatment of these NENs, the use of PET with 18F-l-dihydroxyphenylalanine is being increasingly reported, this approach showing several advantages over conventional imaging. Moreover, changes in tumor biology can be characterized by modifications in receptor or transporter expression on the cell membrane, and evidence has recently emerged that NENs expressing glucose transporters are more aggressive than tumors with low expression of glucose transporters. Therefore, [18F]FDG PET could provide prognostic information useful for stratifying patients according to their risk and for planning the correct therapy. The identification of new radiopharmaceuticals specific for different targets will constitute the basis not only of new diagnostic imaging approaches, but also of new therapeutic applications in NENs, besides radiolabeled peptide receptor radionuclide and 131I-MIBG therapy.

AB - In the field of nuclear medicine, multiagent imaging can disclose enhanced expression of specific target molecules of neoplastic cells. This molecular information can be combined with the information provided by anatomical imaging. Over the past 20 years the use of radiolabeled somatostatin analogs as high-affinity tracers binding specifically to somatostatin receptors has allowed successful molecular imaging of neuroendocrine neoplasms (NENs), initially with single-photon-emitting radiopharmaceuticals, and subsequently also with positron-emitting radiopharmaceuticals. In this context, whole-body somatostatin receptor scintigraphy has changed the diagnostic and therapeutic approach to patients with NENs; moreover, somatostatin analog positron emission tomography (PET) tracers that allow higher spatial resolution imaging have recently been introduced. Nevertheless, several NENs can also be successfully imaged with radioagents that target the catecholamine pathway. Although radioiodinated meta-iodobenzylguanidine (MIBG) is traditionally the first option for radionuclide imaging and treatment of these NENs, the use of PET with 18F-l-dihydroxyphenylalanine is being increasingly reported, this approach showing several advantages over conventional imaging. Moreover, changes in tumor biology can be characterized by modifications in receptor or transporter expression on the cell membrane, and evidence has recently emerged that NENs expressing glucose transporters are more aggressive than tumors with low expression of glucose transporters. Therefore, [18F]FDG PET could provide prognostic information useful for stratifying patients according to their risk and for planning the correct therapy. The identification of new radiopharmaceuticals specific for different targets will constitute the basis not only of new diagnostic imaging approaches, but also of new therapeutic applications in NENs, besides radiolabeled peptide receptor radionuclide and 131I-MIBG therapy.

KW - DOTA PET

KW - F-DOPA PET

KW - MIBG

KW - Neuroendocrine neoplasms

KW - PRRT

KW - Somatostatin receptor scintigraphy

UR - http://www.scopus.com/inward/record.url?scp=84906937776&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84906937776&partnerID=8YFLogxK

U2 - 10.1007/s40336-013-0043-x

DO - 10.1007/s40336-013-0043-x

M3 - Article

AN - SCOPUS:84906937776

VL - 1

SP - 407

EP - 421

JO - Clinical and Translational Imaging

JF - Clinical and Translational Imaging

SN - 2281-5872

IS - 6

ER -